BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases

Biosci Rep. 2019 Nov 29;39(11):BSR20190604. doi: 10.1042/BSR20190604.

Abstract

Transcription factor B-cell lymphoma/leukemia 11A (BCL11A) gene encodes a zinc-finger protein that is predominantly expressed in brain and hematopoietic tissue. BCL11A functions mainly as a transcriptional repressor that is crucial in brain, hematopoietic system development, as well as fetal-to-adult hemoglobin switching. The expression of this gene is regulated by microRNAs, transcription factors and genetic variations. A number of studies have recently shown that BCL11A is involved in β-hemoglobinopathies, hematological malignancies, malignant solid tumors, 2p15-p16.1 microdeletion syndrome, and Type II diabetes. It has been suggested that BCL11A may be a potential prognostic biomarker and therapeutic target for some diseases. In this review, we summarize the current research state of BCL11A, including its biochemistry, expression, regulation, function, and its possible clinical application in human diseases.

Keywords: Clinical application; Expression; Function; Human diseases; Regulation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biomarkers / metabolism*
  • Disease / genetics*
  • Gene Expression Regulation / genetics
  • Humans
  • MicroRNAs / genetics
  • Prognosis
  • Repressor Proteins / genetics*
  • Transcription Factors / genetics

Substances

  • BCL11A protein, human
  • Biomarkers
  • MicroRNAs
  • Repressor Proteins
  • Transcription Factors